Biological
Asthma-related outcome
Biomarkers
Recommendation as per
GRADE methodology
Benralizumab
Dupilumab
Reslizumab
Decrease in severe asthma exacerbations
The higher the blood eosinophils the higher the expected impact
Conditional recommendation
Omalizumab
Decrease in severe asthma exacerbations
The effect does
not depend on blood eosinophils
Conditional
recommendation
Benralizumab
Reslizumab
Improvement in asthma control
The higher the blood eosinophils the higher the expected impact
Conditional recommendation
Benralizumab
Improvement in asthma related QoL
The higher the blood
eosinophils the higher the expected impact
Conditional
recommendation
Dupilumab
Improvement in lung function (FEV1)
Clinically significant effect in asthmatic and adolescent adults with
blood eosinophils > 300 cells/μL and/or with FeNO levels
> 50 ppb
Strong recommendation
Benralizumab
Reslizumab
Improvement in lung function (FEV1)
The higher the blood eosinophils the higher the expected impact
Conditional recommendation
Benralizumab
All asthma related outcomes
Neither the atopic status
or total IgE predict the magnitude of effect
Conditional
recommendation
Omalizumab
All asthma related outcomes
Serum IgE thresholds (within
regulatory limits) do not influence the response
HDM immunotherapy
All asthma related outcomes
No biomarkers
sufficiently predict response to HDM-AIT in HDM-driven allergic asthma
Conditional recommendation
|
|
|
|